Aegon Valuation
Is J060 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of J060 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: J060 (€5.93) is trading below our estimate of fair value (€15.04)
Significantly Below Fair Value: J060 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for J060?
Key metric: As J060 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is J060's PS Ratio? | |
|---|---|
| PS Ratio | 0.8x |
| Sales | €12.73b |
| Market Cap | €9.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.8x |
| Enterprise Value/EBITDA | 501.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does J060's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2x | ||
WUW Wüstenrot & Württembergische | 0.2x | n/a | €1.1b |
TLX Talanx | 0.4x | 8.6% | €20.6b |
2883 KGI Financial Holding | 6.3x | 10.1% | NT$320.9b |
HNR1 Hannover Rück | 1.1x | 2.5% | €30.1b |
J060 Aegon | 0.8x | -4.5% | €9.7b |
Price-To-Sales vs Peers: J060 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2x).
Price to Sales Ratio vs Industry
How does J060's PS Ratio compare vs other companies in the European Insurance Industry?
| 2 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: J060 is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Insurance industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is J060's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.8x |
| Fair PS Ratio | 0.8x |
Price-To-Sales vs Fair Ratio: J060 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €5.93 | €6.52 +9.9% | 10.8% | €8.00 | €5.40 | n/a | 15 |
| Nov ’25 | €5.81 | €6.27 +7.9% | 11.5% | €7.65 | €4.80 | n/a | 15 |
| Oct ’25 | €5.59 | €6.28 +12.3% | 11.5% | €7.65 | €4.80 | n/a | 15 |
| Sep ’25 | €5.48 | €6.26 +14.4% | 11.7% | €7.65 | €4.80 | n/a | 15 |
| Aug ’25 | €5.74 | €6.11 +6.6% | 14.1% | €7.50 | €4.30 | n/a | 15 |
| Jul ’25 | €5.79 | €6.10 +5.4% | 14.4% | €7.60 | €4.30 | n/a | 15 |
| Jun ’25 | €5.91 | €6.06 +2.5% | 15.3% | €8.00 | €4.30 | n/a | 14 |
| May ’25 | €5.79 | €5.90 +1.9% | 12.0% | €7.00 | €4.30 | n/a | 15 |
| Apr ’25 | €5.62 | €5.84 +3.9% | 11.6% | €7.00 | €4.30 | n/a | 15 |
| Mar ’25 | €5.20 | €5.88 +13.1% | 11.3% | €7.00 | €4.30 | n/a | 16 |
| Feb ’25 | €5.42 | €5.76 +6.3% | 11.5% | €7.00 | €4.30 | n/a | 16 |
| Jan ’25 | €5.24 | €5.49 +4.7% | 12.0% | €6.75 | €4.00 | n/a | 15 |
| Dec ’24 | €5.05 | €5.48 +8.5% | 12.0% | €6.75 | €4.00 | n/a | 15 |
| Nov ’24 | €4.59 | €5.38 +17.1% | 13.6% | €6.75 | €3.60 | €5.81 | 15 |
| Oct ’24 | €4.51 | €5.45 +20.8% | 13.3% | €6.75 | €3.60 | €5.59 | 14 |
| Sep ’24 | €4.74 | €5.39 +13.6% | 13.4% | €6.75 | €3.60 | €5.48 | 15 |
| Aug ’24 | €4.94 | €5.38 +8.8% | 14.1% | €6.75 | €3.60 | €5.74 | 14 |
| Jul ’24 | €4.64 | €5.39 +16.0% | 13.8% | €6.75 | €3.60 | €5.79 | 15 |
| Jun ’24 | €4.17 | €5.33 +28.0% | 15.0% | €6.75 | €3.60 | €5.91 | 14 |
| May ’24 | €4.12 | €5.33 +29.6% | 15.1% | €6.75 | €3.60 | €5.79 | 14 |
| Apr ’24 | €3.97 | €5.38 +35.6% | 15.5% | €6.75 | €3.60 | €5.62 | 14 |
| Mar ’24 | €4.91 | €5.38 +9.5% | 15.5% | €6.75 | €3.60 | €5.20 | 14 |
| Feb ’24 | €5.02 | €5.29 +5.4% | 14.7% | €6.75 | €3.60 | €5.42 | 14 |
| Jan ’24 | €4.75 | €5.18 +9.1% | 14.8% | €6.75 | €3.50 | €5.24 | 15 |
| Dec ’23 | €4.70 | €5.19 +10.5% | 14.8% | €6.75 | €3.50 | €5.05 | 15 |
| Nov ’23 | €4.75 | €5.17 +8.7% | 14.6% | €6.50 | €3.50 | €4.59 | 16 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Arch Capital Group
US$37.4b
Provides insurance, reinsurance, and mortgage insurance products worldwide.
RSK
US$96.21
7D
3.5%
1Y
22.6%
Grupo Catalana Occidente
€4.3b
Provides insurance products and services worldwide.
OCZA
€35.90
7D
-1.8%
1Y
14.9%
Sagicor Financial
CA$872.8m
Provides insurance products and related financial services in Jamaica, Barbados, Trinidad, Tobago, other Caribbean region, and the United States.
3RQ
CA$4.26
7D
7.6%
1Y
8.7%